Predictive Value of PIK3CA Mutations for Response to CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
PIK3CA mutation correlates with poor PFS and OS in patients with HR+/HER2- metastatic breast cancer receiving CDK4/6 inhibitors. Therefore, PIK3CA mutation status should be considered a potential predictive biomarker of resistance to CDK4/6 inhibitors.
Authors
- Navkirat Kahlon
- Neehal Wali
- Zaheer Qureshi (ORCID: https://orcid.org/0000-0002-8478-0547)
- Tobechukwu Okobi
- Abdur Jamil
Institutions
- NewYork–Presbyterian Brooklyn Methodist Hospital (US)
- Good Samaritan Medical Center (US)
- Wentworth Douglass Hospital (US)
- St. John's Hospital (US)
- Rowan University (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1097/coc.0000000000001294
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00